PAREXEL International (United Kingdom)

PAREXEL International (United Kingdom)

Parexel is an American contract research organization. It conducts clinical trials on behalf of its pharmaceutical and biotechnology clients to expedite drug development and clinical trial progress. It is one of the largest clinical research organizations in the world. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for PAREXEL International (United Kingdom), United Kingdom, covering academic research published from 2000 to 2024. Read More.


Open Access Percentage

39%


Total
Publications

638


Total Open
Publications

249


Total
Citations

8.5K


Open Access
Percentage

39%


Total
Publications

638


Total Open
Publications

249


Total
Citations

8.5K

Wikipedia

Website

download

Breakdown

23% 14% 1% 62%

Publisher Open

23%

Both

14%

Other Platform Open

1%

Closed

62%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

010203040506070Total Publications
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Open

Closed

Publisher Open

29%OA Journal

OA Journal 29%

67

Hybrid 51%

119

No Guarantees 20%

47

Other Platform Open

Domain 79%

78

Other Internet 25%

25

Institution 18%

18

Public 6%

6

Preprint 0%

0

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
78
DOI
Other Internet
24
Figshare
Public
6
DANS - Data Archiving and Networked Services
Institution
5
Europe PMC
Domain
4
Konstfack University of Arts, Crafts, and Design - Publications
Institution
3
Erasmus University, Rotterdam - RePub
Institution
2
Belarusian State Pedagogical University - Belarusian State Pedagogical University repository
Institution
2
Worktribe - Repository@Hull
Institution
1
VU Research Portal
Institution
1
1 / 3

Data updated 18 August 2025

Share

Share

Share